Jia Jie Biomedical Co., Ltd. (4109.TWO)
TWD 21.85
(0.0%)
TWD 21.85
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -4.48 Million | -8.77 Million | 4.37 Million | 27.1 Million | - |
| Net Income | 146.54 Million | -4.68 Million | 5.29 Million | -41.65 Million | - |
| Depreciation & Amortization | 14.88 Million | 16.86 Million | 13.44 Million | 15.66 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | 35.64 Million | -17.63 Million | -14.56 Million | 47.72 Million | - |
| Other non-cash items | -1.48 Million | -1.12 Million | -457 Thousand | 1.17 Million | - |
| Investing Cash Flow | 2.54 Million | -35.01 Million | -173.04 Million | 7.32 Million | - |
| Investments in PPE | -8.61 Million | -17.85 Million | -1.51 Million | -1.63 Million | - |
| Acquisitions | -31.65 Million | - | -7.51 Million | 3.75 Million | - |
| Investment purchases | -147.39 Million | -30.5 Million | -167.01 Million | - | - |
| Sales/Maturities of investments | 192.01 Million | 15.54 Million | 3.59 Million | - | - |
| Other Investing Activities | -1.85 Million | -2.75 Million | -1.48 Million | 964 Thousand | - |
| Financing Cash Flow | 234.56 Million | -3.72 Million | -2.48 Million | 205.74 Million | - |
| Debt repayment | -75 Million | - | - | -62.8 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 272 Million | - |
| Other Financing Activities | 162.44 Million | - | 1000.00 | - | -6.41 Million |
| Accounts receivables | -1.61 Million | - | - | - | - |
| Accounts payables | 1.08 Million | - | - | - | - |
| Inventory | 1.95 Million | -5.84 Million | -5.74 Million | 38.88 Million | - |
| Other working capital | 35.29 Million | - | - | - | - |
| Cash at beginning of period | 125.53 Million | 172.27 Million | 344.16 Million | 104.37 Million | - |
| Cash at end of period | 354.42 Million | 125.53 Million | 172.27 Million | 344.16 Million | - |
| Capital Expenditure | -8.61 Million | -17.85 Million | -1.51 Million | -1.63 Million | - |
| Effect of forex changes on cash | -3.73 Million | 781 Thousand | -729 Thousand | -387 Thousand | - |
| Net cash flow / Change in cash | 228.89 Million | -46.74 Million | -171.88 Million | 239.78 Million | - |
| Free Cash Flow | -13.1 Million | -26.63 Million | 2.85 Million | 25.46 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 219.19 Million | 17.97 Million | 146.54 Million | 158.16 Million | 21.45 Million | -11.23 Million |
| Depreciation & Amortization | 4.01 Million | 4.04 Million | 14.88 Million | 3.61 Million | 4.01 Million | 3.47 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 14.54 Million | -4.63 Million | 35.64 Million | 29.19 Million | 7.48 Million | 3.97 Million |
| Other non-cash items | -941 Thousand | 456 Thousand | -1.48 Million | -440 Thousand | -97 Thousand | -630 Thousand |
| Investing Cash Flow | 44.88 Million | -41.23 Million | 2.54 Million | -88.44 Million | 19.1 Million | 48.18 Million |
| Investments in PPE | -1.04 Million | -805 Thousand | -8.61 Million | -1.61 Million | -5.58 Million | -950 Thousand |
| Acquisitions | - | -41.29 Million | -31.65 Million | - | - | - |
| Investment purchases | -9.65 Million | - | -147.39 Million | -132.11 Million | -15.28 Million | - |
| Sales/Maturities of investments | 54.7 Million | 1.54 Million | 192.01 Million | 78.14 Million | 40.18 Million | 48.88 Million |
| Other Investing Activities | 884 Thousand | -675 Thousand | -1.85 Million | -1.21 Million | -212 Thousand | 249 Thousand |
| Financing Cash Flow | -35.67 Million | -72.38 Million | 234.56 Million | 236.72 Million | -898 Thousand | -630 Thousand |
| Debt repayment | -35 Million | -40 Million | -75 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 130.73 Million | - | - | - | - |
| Other Financing Activities | -673 Thousand | -162.44 Million | 162.44 Million | - | - | - |
| Accounts receivables | -19.85 Million | - | - | - | - | - |
| Accounts payables | -3.11 Million | - | - | - | - | - |
| Inventory | 4.93 Million | 1.85 Million | 1.95 Million | -1 Million | 1.1 Million | 2.05 Million |
| Other working capital | 32.58 Million | - | - | - | - | - |
| Cash at beginning of period | 259.01 Million | 354.42 Million | 125.53 Million | 217.15 Million | 168.54 Million | 125.22 Million |
| Cash at end of period | 295.1 Million | 259.01 Million | 354.42 Million | 354.42 Million | 217.15 Million | 168.54 Million |
| Capital Expenditure | -1.04 Million | -805 Thousand | -8.61 Million | -1.61 Million | -5.58 Million | -950 Thousand |
| Effect of forex changes on cash | 175 Thousand | 1.05 Million | -3.73 Million | -2.38 Million | -1.55 Million | 407 Thousand |
| Net cash flow / Change in cash | 36.09 Million | -95.41 Million | 228.89 Million | 137.27 Million | 48.6 Million | 43.31 Million |
| Free Cash Flow | 25.66 Million | 16.34 Million | -13.1 Million | -10.24 Million | 26.37 Million | -5.59 Million |
3223
RAYMOND
KHAITANLTD
CHMI-PB
TMD
3114